CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Viatris INC (VTRS) / cenerimod
Forward catalyst · VTRS

cenerimod

Sponsor Viatris INC · listed as VTRS

READOUT Phase 3 Confidence: medium Source: clinicaltrials

cenerimod is a clinical-stage drug asset sponsored by Viatris INC, listed as VTRS. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Oct 31, 2026 (day precision, medium confidence), tied to trial NCT05648500. The asset is in Phase 3 and currently active not recruiting, studied in Lupus Erythematosus, Systemic. It appears across 4 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-10-31
As disclosedOct 31, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05648500
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorViatris Innovation GmbH
Listed asVTRS
Condition(s)Lupus Erythematosus, Systemic
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More VTRS catalysts